01 / 01

REGEnLIFE

Thinking beyond the brain: The photomedical device of REGEnLIFE could monitor gut microbiota dysbiosis during Alzheimer’s disease to protect from memory loss

Thinking beyond the brain: The photomedical device of REGEnLIFE could monitor gut microbiota dysbiosis during Alzheimer’s disease to protect from memory loss

Barcelona, Spain. October 27, 2018. The REGEnLIFE company participated on October, 27thto the Clinical Trials in Alzheimer’s Disease (CTAD) conference in Barcelona, Spain. Clinical trial teams worldwide discussed new results for the development of the next generation of treatments for Alzheimer’s Disease in order to identify new candidate therapeutic strategies....

Oct , 27
REGEnLIFE presenting at ‘AAT-AD/PD’ Congress in Torino

REGEnLIFE presenting at ‘AAT-AD/PD’ Congress in Torino

REGEnLIFE participated at ‘Advances in Alzheimer’s and Parkinson’s Therapies’  Congress in Torino, Italy, and presented a poster of ‘Neuroprotective effect of a new photo-biomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support : a novel hypothesis for therapeutic approach of Alzheimer’s disease’ study....

Mar , 15
THINKING OUTSIDE THE BOX

THINKING OUTSIDE THE BOX

REGEnLIFE presentation selected for the highlights of the ‘Clinical Trials on Alzheimer’s Disease’ (CTAD) international conference Read PDF...

Nov , 4